Recommended Products
ligand
(Trimethylammoniumethyl)
Quality Level
description
strong anion exchanger, suspension in 20% ethanol and 150 mM NaCl (40-90 µm)
sterility
sterile (Caustic Stable)
form
resin
specific analyte(s)
MAbs
parameter
180 cm/hr flow rate
8 bar max. pressure
matrix active group
methacrylate
mean particle size
40-90 μm
capacity
180 mg binding capacity (BSA/mg of resin)
transition temp
flash point 35 °C (calculated)
density
1.430 g/cm3 at 20 °C
bulk density
1000 kg/m3
application(s)
recombinant protein
separation technique
anion exchange
strong anion exchange
storage temp.
2-30°C
Looking for similar products? Visit Product Comparison Guide
Related Categories
General description
Features and Benefits
- Efficiently capture target protein and remove viruses, DNA, and endotoxins with its tentacle technology resulting in better production yields and high throughput
- Reduce operating costs and resin replacement with enduring durability - allowing for multiple cycles of column regeneration and sanitization
- Compatibility with 2.5 % (v/v) aqueous benzyl alcohol containing 150 mM NaCl storage solution
Due to the titration behavior of Fractogel® EMD TMAE Hicap (M) the ion exchange capacity can be used from pH 2 to 12. The separation of proteins is based on reversible electrostatic interactions between the negatively charged regions of the proteins′ surface and the support. Proteins are retained efficiently on Fractogel® EMD TMAE Hicap (M) when the pH of the buffer is about 1 unit above their isoelectric points (pl).
The strength of the binding depends on the following:
- the buffer system
- pH value of the buffer which determines the surface charge of the protein
- the concentration of the counter ions
- the charge density on the support (protein binding capacity)
Packaging
- 1.10316.0100: Fractogel® EMD TMAE Hicap (M) Resin 100ml
- 1.10316.0010: Fractogel® EMD TMAE Hicap (M) Resin 10ml
- 1.10316.0500: Fractogel® EMD TMAE Hicap (M) Resin 500ml
- 1.10316.5000: Fractogel® EMD TMAE Hicap (M) Resin 5L
Analysis Note
Microscopic evaluation: Uniform spherical particles,no agglomerates,no fines
Extractable matter (water): ≤ 0.03 %
Cerium: ≤ 1 µg/g
Pressure drop(column: ID=1.6 cm, L=10 cm at 5 ml/min): ≤ 1 bar
Particle size (d10): 37 - 45 µm
Particle size (d50): 48 - 60 µm
Particle size (d90): 63 - 77 µm
Colony forming units (TAMC + TYMC): ≤ 100 CFU/ml
Endotoxins: ≤ 1.00 EU/ml
Protein binding capacity (bovine serum albumin): 160 - 200 mg/ml
Functional test (b:a): ≤ 0.25
Functional test: Separation of conalbumin and human serum albumin
Legal Information
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Flam. Liq. 3
Storage Class Code
3 - Flammable liquids
WGK
WGK 1
Flash Point(F)
95.0 °F
Flash Point(C)
35 °C
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Articles
Influenza vaccines are commonly made using egg-based and cell-based manufacturing strategies. Find step-by-step information on the manufacturing process for each method.
A custom-designed cost model is used to explore the economics of vaccine manufacturing across several different modalities including mRNA. The model enables greater process understanding, simulates bottlenecks, and helps to optimize production efficiency.
Learn more one the attenuated viral vaccines manufacturing process: cell culture, clarification, nuclease treatment, chromatography, and sterile filtration.
This technical article breaks down the steps of upstream and downstream bioprocessing and formulation of virus-like particle vaccines.
Related Content
This technical article breaks down the adenovirus vaccine manufacturing process and provides a case study on developing an accelerated and cost-effective single-use adenoviral vector vaccine.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service